65
Participants
Start Date
January 26, 2023
Primary Completion Date
December 31, 2024
Study Completion Date
June 30, 2025
SLN124
SLN124 is a double-stranded small interfering ribonucleic acid (siRNA) targeting transmembrane protease, serine 6 (TMPRSS6) messenger ribonucleic acid (mRNA).
Placebo
sodium chloride, solution for injection
RECRUITING
MHAT Dr Nikola Vasiliev AD, Kyustendil
RECRUITING
Peter MacCallum Cancer Centre, Melbourne
RECRUITING
Alfred Health, Melbourne
RECRUITING
Epworth HealthCare, Richmond
RECRUITING
Medical Centre Leo Clinic EOOD, Plovdiv
RECRUITING
Pindara Private Hospital, Benowa
RECRUITING
Ashford Cancer Centre Research, Kurralta Park
RECRUITING
Linear Clinical Research, Nedlands
RECRUITING
Mount Sinai Hospital, New York
RECRUITING
Hospital Sultanah Nur Zahirah, Kuala Terengganu
RECRUITING
Hospital Tengku Ampuan Afzan, Kuantan
NOT_YET_RECRUITING
Duke Cancer Institute, Durham
RECRUITING
University of Michigan, Ann Arbor
RECRUITING
Hospital Ampang, Ampang
COMPLETED
North Houston Cancer Clinics, Huntsville
RECRUITING
Renovatio Clinical, The Woodlands
RECRUITING
Hospital Sultanah Aminah, Johor Bahru
RECRUITING
Hospital Umum Sarawak, Kuching
RECRUITING
Uniwersyteckie Centrum Klinlczne, Gdansk
RECRUITING
PRATIA Hematologia Sp. z o. o., Katowice
RECRUITING
Samodzielny Publiczny Szpital Kliniczny Nr 1 w Lublinie, Lublin
RECRUITING
Centrum Medyczne Pratia Poznan Sp. z o. o., Skorzewo
RECRUITING
Specjalistyczny Szpital Im Dra. A., Wałbrzych
Silence Therapeutics plc
INDUSTRY